First-In-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-Her3 Monoclonal Antibody, in Patients With Metastatic or Advanced HER3-Positive Solid Tumors
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-1683
Full Text
Open PDFAbstract
Available in full text
Date
October 13, 2015
Authors
Publisher
American Association for Cancer Research (AACR)